A new pharma leader

/ Work / AXIM Biotechnologies

Creating and communicating a consistent brand story to investors and the media

Creating Advantage

Media interviews enhanced the company’s profile and credibility

Secured additional private funding

Market cap increased from $12M to $500M+ in just over six months

Stock trading has quadrupled since our engagement

Project Leader

Despite groundbreaking work, AXIM's lack of profile was depressing its stock price. The company was thought of as ‘just another cannabis company’ without full appreciation of the breadth of its pharmaceutical, nutraceutical and alternative energy offer, leading to uncertainty over whether the company had sufficient capital to carry out existing and new clinical trials.

We created a communications plan to deliver the AXIM story to investor and media audiences, positioning the company as a leader in pharma cannabis R&D and products.

Our program included targeted media relations, contributed content and newsjacking, executive profiling through speaking opportunities at investment conferences, and analyst relations. We also advised on the optimum pathway for uplisting, and facilitated dialogue with NYSE/NASDAQ.